Trimethoprim

Shigellosis, Nocardiosis, Brucellosis + 16 more

Treatment

17 FDA approvals

16 Active Studies for Trimethoprim

What is Trimethoprim

Trimethoprim

The Generic name of this drug

Treatment Summary

Trimethoprim is an antibiotic used to fight bacterial infections. It works by decreasing the production of a certain enzyme in bacteria which stops them from making DNA and surviving. Trimethoprim is often used together with another antibiotic called sulfamethoxazole, but it can also be used alone to treat and prevent urinary tract infections. It has a similar structure and chemical makeup to another medication called pyrimethamine which is used to treat malaria.

Septra DS

is the brand name

image of different drug pills on a surface

Trimethoprim Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Septra DS

Trimethoprim

1973

343

Approved as Treatment by the FDA

Trimethoprim, also called Septra DS, is approved by the FDA for 17 uses including Cholera and susceptible Enteritis infectious caused by Shigella sonnei .

Cholera

Used to treat susceptible Cholera in combination with Sulfamethoxazole

susceptible Enteritis infectious caused by Shigella sonnei

Used to treat susceptible Enteritis infectious caused by Shigella sonnei in combination with Sulfamethoxazole

Fluid replacement therapy

Used to treat Fluid replacement therapy in combination with Sulfamethoxazole

Urinary tract infection

Used to treat Urinary Tract Infection caused by susceptible bacteria in combination with Sulfamethoxazole

Nocardiosis

Used to treat Nocardiosis in combination with Sulfamethoxazole

Pneumonia, Pneumocystis

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Genus Pneumocystis

Used to treat risk of Pneumocystis jiroveci pneumonia (PCP) in combination with Sulfamethoxazole

Otitis Media

Used to treat Acute Otitis Media caused by susceptible bacteria in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Electrolyte replacement

Used to treat Electrolyte replacement in combination with Sulfamethoxazole

Pneumocystis Jirovecii Pneumonia

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Shigellosis

Used to treat Dysentery, Bacillary in combination with Sulfamethoxazole

Bronchitis

Used to treat Acute Exacerbation of Chronic Bronchitis (AECB) caused by susceptible bacteria in combination with Sulfamethoxazole

Diarrhea

Used to treat susceptible Travelers' Diarrhea caused by Enterotoxigenic E. Coli (ETEC) Infection in combination with Sulfamethoxazole

susceptible Enteritis infectious caused by Shigella flexneri

Used to treat susceptible Enteritis infectious caused by Shigella flexneri in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Immunocompromised

Used to treat Immunocompromised in combination with Sulfamethoxazole

Effectiveness

How Trimethoprim Affects Patients

Trimethoprim works by blocking an essential step in bacteria’s ability to make proteins and genetic material. It is effective against some types of bacteria, although some may develop resistance to it. Rarely, it can cause blood disorders such as low platelet and white blood cell counts. If you experience symptoms like sore throat, fever, pale skin, and bruising, be sure to tell your doctor right away. Before taking trimethoprim, it’s important to consult local antibiotic sensitivity testing to make sure it will be effective against the bacteria causing your infection.

How Trimethoprim works in the body

Trimethoprim stops bacteria from making the proteins and genetic material they need to survive. It does this by blocking the action of an enzyme that helps create a molecule necessary for bacterial growth. Trimethoprim is usually given with another drug, sulfamethoxazole, which blocks the step before trimethoprim in bacterial protein synthesis. Together, these two drugs stop bacteria from creating the proteins and genetic material they need to live. When taken alone, trimethoprim only slows down bacteria; but when taken with sulfamethoxazole, it kills them.

When to interrupt dosage

The recommended measure of Trimethoprim is contingent upon the diagnosed disorder, such as Urinary tract infection, Immunocompromised and Pneumocystis Jirovecii Pneumonia. The amount of dosage fluctuates, as per the technique of delivery (e.g. Tablet - Oral or Tablet) detailed in the subsequent table.

Condition

Dosage

Administration

Conjunctivitis, Bacterial

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Pneumonia, Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Brucellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Immunocompromised

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Nocardiosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

bacterial blepharitis caused by susceptible bacteria

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Diarrhea

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Shigellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Electrolyte replacement

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Fluid replacement therapy

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Genus Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Bacterial conjunctivitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Bronchitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

susceptible Enteritis infectious caused by Shigella flexneri

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

susceptible Enteritis infectious caused by Shigella sonnei

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Otitis Media

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Cholera

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Warnings

Trimethoprim has eight contraindications and should not be used when viewing any of the conditions in the subsequent table.

Trimethoprim Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

Purpura, Thrombocytopenic, Idiopathic

Do Not Combine

hepatic damage

Do Not Combine

Megaloblastic anemia caused by Folate deficiency

Do Not Combine

unable to monitor renal function

Do Not Combine

Disease

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

There are 20 known major drug interactions with Trimethoprim.

Common Trimethoprim Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Trimethoprim.

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Trimethoprim.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Trimethoprim.

Cisplatin

Major

The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim.

Clofarabine

Major

The serum concentration of Clofarabine can be increased when it is combined with Trimethoprim.

Trimethoprim Toxicity & Overdose Risk

The lowest toxic dose of trimethoprim in mice and rats is 2764mg/kg and greater than 5300mg/kg respectively. Symptoms of an overdose may include nausea, vomiting, dizziness, headaches, mental depression, confusion, and a decrease in bone marrow production. Treatment should involve supportive care, and the stomach may need to be flushed out with lavage. Increasing the acidity of the urine may help the body eliminate trimethoprim more quickly. Dialysis may help remove some of the drug, but it is only moderately effective.

image of a doctor in a lab doing drug, clinical research

Trimethoprim Novel Uses: Which Conditions Have a Clinical Trial Featuring Trimethoprim?

8 active trials are currently taking place to investigate the possible application of Trimethoprim to treat Shigella flexneri-induced Enteritis, Bacterial-induced Blepharoconjunctivitis and Diarrhea.

Condition

Clinical Trials

Trial Phases

Urinary tract infection

0 Actively Recruiting

Bacterial conjunctivitis

0 Actively Recruiting

Bronchitis

0 Actively Recruiting

Nocardiosis

0 Actively Recruiting

Shigellosis

0 Actively Recruiting

Brucellosis

0 Actively Recruiting

bacterial blepharitis caused by susceptible bacteria

0 Actively Recruiting

Immunocompromised

2 Actively Recruiting

Phase 1, Not Applicable

Otitis Media

0 Actively Recruiting

Genus Pneumocystis

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

Fluid replacement therapy

0 Actively Recruiting

Cholera

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

susceptible Enteritis infectious caused by Shigella sonnei

0 Actively Recruiting

Pneumonia, Pneumocystis

2 Actively Recruiting

Phase 3, Phase 4

susceptible Enteritis infectious caused by Shigella flexneri

0 Actively Recruiting

Electrolyte replacement

0 Actively Recruiting

Diarrhea

12 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 1

Trimethoprim Reviews: What are patients saying about Trimethoprim?

5

Patient Review

2/10/2014

Trimethoprim for Urinary Tract Infection

I take it just once a day to keep things working properly. The only downside is that I sometimes experience a lot of gas.

5

Patient Review

3/1/2014

Trimethoprim for Urinary Tract Infection

Blood and cloudy urine cleared up within a week of taking this medication, as directed. No bacteria was found on the culture. Does cause gas; however, probiotics seemed to help with that issue.

5

Patient Review

2/19/2019

Trimethoprim for Bacterial Urinary Tract Infection

I've been using this treatment for six months now and I haven't had a UTI in that entire time. Prior to this, I was getting them every few month; some days were even really bad.

5

Patient Review

8/28/2019

Trimethoprim for Bacterial Urinary Tract Infection

I didn't have any negative reactions, which was great.

4.7

Patient Review

4/28/2014

Trimethoprim for Bacterial Urinary Tract Infection

I've been taking this for four months now to prevent UTIs. I generally take it before bed. Recently, I developed a rash on my neck that's been pretty itch and won't go away no matter what I do. It might be from sun exposure, so I'm going to stop taking the medication and hope that the rash goes away and that I don't get a UTI again.

4.3

Patient Review

12/5/2013

Trimethoprim for Bacterial Urinary Tract Infection

I was put on this medication after having four UTIs in three months. It's been four months since then and I haven't had another infection, which is amazing. I'll probably be on this medication for the rest of my life.

4.3

Patient Review

4/6/2016

Trimethoprim for Bacterial Urinary Tract Infection

The drug did clear up the infection, but I found it hard to take because it started dissolving quickly and often stuck to the back of my tongue.

4.3

Patient Review

9/21/2017

Trimethoprim for Urinary Tract Infection Prevention

This chronic UTI treatment helps to prevent breakthrough infections for patients who have to self-catheterize regularly.

3

Patient Review

1/8/2014

Trimethoprim for Bacterial Urinary Tract Infection

I'm on my second day of treatment, and I feel faint every hour. I also can't keep food down, and my kidneys are still hurting. Additionally, there's a burning sensation in my belly and I feel dizzy.

3

Patient Review

7/15/2015

Trimethoprim for Urinary Tract Infection

The tablets cleared the infection, but I felt awful afterward. Total fatigue and some nausea. I stopped taking them after five days and felt much better immediately.

1.7

Patient Review

8/11/2022

Trimethoprim for Urinary Tract Infection

These antibiotics were an awful experience for me. I started having burning and spasms in my vagina, then severe lower abdominal pain. I ended up vomiting 20 times and had to go to the emergency room. Since then, I've been constantly in pain and have had bladder pressure.

1

Patient Review

7/4/2013

Trimethoprim for Urinary Tract Infection

I had a severe allergic reaction to this medication and now have to wear an allergy bracelet. Just half a tablet caused my mouth to swell so much that I couldn't eat, and I also suffered from extreme itching in personal areas. It took a week of large doses of steroids for me to start feeling any relief.

1

Patient Review

9/12/2019

Trimethoprim for Infection of Urinary Tract due to Enterobacter Cloacae

I've been on so many antibiotics at this point and they all make me feel terrible. I get nauseous, shaky, and my heart races. This last one prescribed by the doctor didn't even help with the nausea.

1

Patient Review

3/1/2019

Trimethoprim for Bacterial Urinary Tract Infection

Almost immediately after starting this medication, I began to experience heart palpitations and irregular heartbeat. When I called my GP about it, he brushed me off and said it wasn't possible. Even though that's a listed side effect on the bottle! Irregular heartbeat is even more common than a simple headache. So not only am I in pain, but now I'm also terrified and exhausted from lack of sleep. Cannot wait for this poison to leave my system.

1

Patient Review

9/7/2018

Trimethoprim for Bacterial Urinary Tract Infection

I had an allergic reaction to this medication and it caused me to break out in red blotches all over my body.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about trimethoprim

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of antibiotic is trimethoprim?

"It is an antibiotic that helps to treat infections and is often used in combination with another medication."

Answered by AI

What are the common side effects of trimethoprim?

"Diarrhea, nausea, vomiting, stomach upset, loss of appetite, changes in taste, and headache may occur. If you experience any of these effects for an extended period of time, or if they worsen, tell your doctor or pharmacist."

Answered by AI

How long does it take for trimethoprim to work for urinary tract infection?

"If you take trimethoprim and your symptoms do not improve within 48 hours, you should see a doctor."

Answered by AI

What is the drug trimethoprim used for?

"It comes as tablets. Trimethoprim is an antibiotic. It is used to treat and prevent urinary tract infections (UTIs), such as cystitis. Occasionally, trimethoprim is used to treat other types of infections, such as chest infections and acne. Trimethoprim is available on prescription. It comes as tablets."

Answered by AI

Clinical Trials for Trimethoprim

Image of McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital in Montreal, Canada.

Systemic Corticosteroids for Pneumocystis Pneumonia

18+
All Sexes
Montreal, Canada

The HOW LONG trial is an international, multicenter, Phase IV randomized clinical trial evaluating the optimal duration of adjunctive systemic corticosteroids in immunocompromised adults with severe Pneumocystis jirovecii pneumonia (PCP) who demonstrate early clinical recovery. Participants who no longer require supplemental oxygen by day 10 of corticosteroid therapy are randomized to discontinue corticosteroids at day 10 (or hospital discharge, if earlier) versus continue corticosteroids for a total of 21 days. The trial assesses whether earlier discontinuation reduces steroid-related complications while maintaining clinical outcomes.

Phase 4
Waitlist Available

McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Have you considered Trimethoprim clinical trials?

We made a collection of clinical trials featuring Trimethoprim, we think they might fit your search criteria.
Go to Trials
Image of University of Maryland, School of Medicine, Center for Vaccine Development and Global Health in Baltimore, United States.

Vaccine for E. coli Infections

18 - 49
All Sexes
Baltimore, MD

The study is designed to evaluate the safety, immunogenicity, and efficacy of the intramuscular administration of a CS6 based vaccine (CssBA) against ETEC co-administered with double mutant labile toxin (dmLT) in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. Approximately 72 adult participants, divided into 4 cohorts of 18, will be randomized 1:1 to receive vaccine (45 micrograms CssBA with 0.5 micrograms dmLT) or placebo (normal saline) on an outpatient basis. All participants will receive 3 intramuscular (IM) doses of vaccine or placebo at 3-week intervals (days 1, 22 and 43). Following vaccination, participants will be followed as outpatients for safety using a memory aid from the time of each vaccination through 7 days post each vaccination. Approximately 28 days (plus or minus 1 day) after receipt of the 3rd dose of study agent, participants meeting challenge criteria will be admitted to an inpatient unit and be administered an oral dose of 1 x 10\^10 cfu (colony-forming unit) of ETEC strain B7A. Five days after challenge, participants will be treated with ciprofloxacin, except in cases of known allergy or intolerance. Participants will be discharged from the inpatient unit when they have completed their 3-day antibiotic course and are able to care for themselves. After discharge from the inpatient unit, participants will return for clinic visits and have a phone visit to provide any updates on medication, medical history and AE/SAEs. The primary objectives are: 1) Estimate CssBA+dmLT efficacy in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. 2) Evaluate the safety of intramuscular injection of CssBA+dmLT.

Phase 2
Waitlist Available

University of Maryland, School of Medicine, Center for Vaccine Development and Global Health (+1 Sites)

Have you considered Trimethoprim clinical trials?

We made a collection of clinical trials featuring Trimethoprim, we think they might fit your search criteria.
Go to Trials
Image of McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) in Montreal, Canada.

Low-Dose Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia

18 - 100
All Sexes
Montreal, Canada

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX. Reduced treatment doses of TMP-SMX for PJP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PJP for the primary outcome of death, new mechanical ventilation, and change of treatment.

Phase 3
Waitlist Available

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

Emily G McDonald, MD MSc

Have you considered Trimethoprim clinical trials?

We made a collection of clinical trials featuring Trimethoprim, we think they might fit your search criteria.
Go to Trials